Content area
Full text
A new study shows that patients regain around 14% of the weight lost with tirzepatide, the active ingredient in Eli Lilly's drug Mounjaro, one year after stopping treatment. The study was conducted by the pharmaceutical company itself and published this week in the journal JAMA.
Mounjaro was approved this year in Brazil for patients with type 2 diabetes, but has not yet arrived in the country. The official indication of tirzepatida for weight loss is being analyzed by Anvisa. In the USA, approval for the treatment of obesity was granted in November, and the drug for this public is now marketed under the name Zepbound.
Tirzepatide is a substance similar to semaglutide, present in Novo Nordisk's drugs Ozempic and Wegovy. They all simulate the GLP-1 hormone, which is...